Naslov
Stable gastric pentadecapeptide BPC 157 as a therapy for the disable myotendinous junctions in rats

Autori
Japjec, Mladen ; Horvat Pavlov, Katarina ; Petrović, Andreja ; Starešinić, Mario ; Šebečić, Božidar ; Buljan, Matko ; Vraneš, Hrvoje ; Giljanović, Ana ; Drmić, Domagoj ; Japjec, Miroslav ; Prtorić, Andreja ; Lovrić, Eva ; Batelja Vuletić, Lovorka ; Dobrić, Ivan ; Boban Blagaić, Alenka ; Škrtić, Anita ; Seiwerth, Sven ; Predrag, Sikirić

Izvornik
Biomedicines (2227-9059) 9 (2021), 11; 1547, 30

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
nitric oxide ; oxidative stress ; BPC 157 therapy ; myotendinous junctions ; leg contracture ; walking recovery index

Sažetak
(1) Aim: The stable gastric pentadecapeptide BPC 157 is known to heal transected muscle, tendon, and ligament. Thereby, in this study, we investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats. (2) Materials and Methods: Myotendinous junction defect, which cannot heal spontaneously in rats, as evidenced with consistent macro/microscopic, biomechanical, functional assessments, eNOS, and COX-2 mRNA levels and oxidative stress and NO-levels in the myotendinous junctions. BPC 157 (10 g/kg, 10 ng/kg) regimen was given (i) intraperitoneally, first application immediately after surgery, last 24 h before sacrifice ; (ii) per-orally, in drinking water (0.16 g/mL, 0.16 ng/mL, 12 mL/rat/day), till the sacrifice at 7, 14, 28 and 42 postoperative days. (3) Results: These BPC 157 regimens document prominent therapy effects (macro/microscopic, biomechanical, functional much like eNOS and COX-2 mRNA levels and counteracted oxidative stress and NO-levels in the myotendinous junctions), while controls have a poor presentation. Especially, in rats with the disabled myotendinous junction, along with full functional recovery, BPC 157 counteracts muscle atrophy that is regularly progressive and brings muscle presentation close to normal. Accordingly, unlike the perilous course in controls, those rats, when receiving BPC 157 therapy, exhibit a smaller defect, and finally defects completely disappear. Microscopically, there are no more inflammatory infiltrate, well-oriented recovered tissue of musculotendon junction appears in BPC 157 treated rats at the 28 days and 42 days. (4) Conclusions: BPC 157 restores myotendinous junction in accordance with the healing of the transected muscle, tendon, and ligament.

Izvorni jezik
Engleski

Znanstvena područja
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)

POVEZANOST RADA